AbbVie's Skyrizi maintains momentum despite J&J's Icotyde competition. Q2 Skyrizi sales hit $5.5B as the company raises full-year revenue forecast.
If AbbVie executives are bothered by growing threats to their immunology powerhouse, they aren’t letting on.
Earlier this year, analysts were pondering …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Since they were approved four months apart in 2019, AbbVie’s Skyrizi and Rinvoq have been joined at the hip, central to the…
Two months after UCB revealed the success of Bimzelx in a head-to-head trial aga | Two months after UCB revealed the success of…
FDA approves AbbVie Skyrizi for pediatric psoriasis, while EU’s CHMP backs Rinvoq for vitiligo and alopecia. Read the latest…
In this week’s edition of InnovationRx, we look at the boom in autoimmune disease therapies, OpenAI’s healthcare push, Vertex’s…
Better-than-expected sales helped Biogen regain the support of investors, while AstraZeneca and GSK worked to convince Wall…
AbbVie strikes a $10.9B deal for Apogee, adding a long-acting IL-13 drug to its Humira-Skyrizi-Rinvoq I&I franchise.
